| 36.86 -0.67 (-1.79%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.13 |
1-year : | 47.57 |
| Resists | First : | 37.78 |
Second : | 40.72 |
| Pivot price | 36.77 |
|||
| Supports | First : | 33.02 |
Second : | 27.48 |
| MAs | MA(5) : | 37.86 |
MA(20) : | 37.07 |
| MA(100) : | 40.15 |
MA(250) : | 46.35 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 56.5 |
D(3) : | 66.8 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 67.87 | Low : | 30.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRSP ] has closed below upper band by 48.6%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 37.24 - 37.42 | 37.42 - 37.57 |
| Low: | 35.85 - 36.1 | 36.1 - 36.3 |
| Close: | 36.51 - 36.89 | 36.89 - 37.2 |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Sat, 24 May 2025
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 14,125 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Sat, 24 May 2025
Rafferty Asset Management LLC Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Sat, 24 May 2025
Ameriprise Financial Inc. Has $8.07 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Wed, 21 May 2025
CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug - MSN
Mon, 19 May 2025
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies - GlobeNewswire
Tue, 13 May 2025
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 8.537e+007 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 20,310 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.5516e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -17 % |
| Return on Assets (ttm) | 158.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 3.767e+007 % |
| Gross Profit (p.s.) | -4.56 |
| Sales Per Share | 0.43 |
| EBITDA (p.s.) | -5.18 |
| Qtrly Earnings Growth | -4.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 85.31 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.076e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|